The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Epigenetic modification in gliomas: role of the histone methyltransferase EZH2
Abstract
Introduction Gliomas are characterized by increased anaplasia, malignization, proliferation and invasion. They exhibit high resistance to standard treatment with combinations of radiotherapy and chemotherapy. They are currently the most common primary malignancy tumors in the brain that is related to a high mortality rate. Recently, increasing evidence suggests that EZH2 is involved in a number of glioma cell processes, including proliferation, apoptosis, invasion and angiogenesis. Areas covered In this review, we emphasize the role of EZH2 in gliomas. We also address that EZH2 interacting with DNA methylation mediates transcriptional repression of specific genes in gliomas, and the regulation of EZH2 by microRNAs in gliomas. Expert opinion Although the exact role of EZH2 in gliomas has not been fully elucidated, to understand the role of EZH2 proteins in epigenetic modification will provide valuable insights into the causes of gliomas, and pave the way to the potential future applications of EZH2 in the treatment of gliomas.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aberrations in PRCs’ functionality were linked to several human cancers,120,121 significantly contributing to the self-renewal/differentiation balance of cancer stem cells,122,123,124 including GSCs.125”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [125]
Citations
Cites
Epigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143
TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity
Williams, K., Christensen, J., Pedersen, M. T., Johansen, J. V., Cloos, P. A. C., Rappsilber, J., & Helin, K. (2011) · Nature · doi:10.1038/nature10066 · Cited by 1,021
Research works printed but not linked: 94
- Hamza MA, 2014, Curr Oncol Rep, 16, 379, 10.1007/s11912-014-0379-z · DOI
- 10.1146/annurev.pathol.1.110304.100043 · DOI
- 10.1007/s00401-007-0243-4 · DOI
- 10.2353/ajpath.2010.100680 · DOI
- Gupta K, 2012, J Cancer Res Clin Oncol, 138, 1971, 10.1007/s00432-012-1323-y · DOI
- 10.1309/6JNX4PA60TQ5U5VG · DOI
- Perry A, 2003, Neuro Oncol, 5, 168, 10.1215/S1152851702000443 · DOI
- 10.1097/00130404-200303000-00003 · DOI
- Dolecek TA, 2012, Neuro Oncol, 14, v1, 10.1093/neuonc/nos218 · DOI · Paper page
- 10.1200/JCO.2011.38.4818 · DOI
- Smith JS, 2008, J Clin Oncol, 26, 1338, 10.1200/JCO.2007.13.9337 · DOI · Paper page
- 10.1016/S0140-6736(05)67070-5 · DOI · Paper page
- Weller M, 2012, Cancer J, 18, 40, 10.1097/PPO.0b013e318243f6c9 · DOI
- Hadjipanayis CG, 2009, J Mol Med (Berl), 87, 363, 10.1007/s00109-009-0440-9 · DOI
- 10.1016/j.bcp.2010.04.035 · DOI
- 10.1016/S1470-2045(11)70257-1 · DOI
- 10.1038/nrc2499 · DOI
- Natsume A, 2013, Cancer Res, 73, 4559, 10.1158/0008-5472.CAN-13-0109 · DOI
- Vescovi AL, 2006, Nat Rev Cancer, 6, 425, 10.1038/nrc1889 · DOI
- Cardoso C, 2000, Eur J Hum Genet, 8, 174, 10.1038/sj.ejhg.5200439 · DOI
- 10.1038/nature09784 · DOI · Paper page
- 10.1126/science.1076997 · DOI · Paper page
- 10.1101/gad.1035902 · DOI · Paper page
- Muller J, 2002, Cell, 111, 197, 10.1016/S0092-8674(02)00976-5 · DOI
- Lachner M, 2001, Nature, 410, 116, 10.1038/35065132 · DOI · Paper page
- Sauvageau M, 2010, Cell Stem Cell, 7, 299, 10.1016/j.stem.2010.08.002 · DOI · Paper page
- Wang H, 2004, Nature, 431, 873, 10.1038/nature02985 · DOI
- 10.1158/1078-0432.CCR-10-2156 · DOI
- 10.1073/pnas.1116418109 · DOI
- 10.1038/ng.518 · DOI
- 10.1038/ng.892 · DOI
- Wigle TJ, 2011, FEBS Lett, 585, 3011, 10.1016/j.febslet.2011.08.018 · DOI
- 10.1182/blood-2010-11-321208 · DOI
- Arisan S, 2005, Urol Int, 75, 252, 10.1159/000087804 · DOI
- 10.1073/pnas.1933744100 · DOI · Paper page
- Matsukawa Y, 2006, Cancer Sci, 97, 484, 10.1111/j.1349-7006.2006.00203.x · DOI
- Raman JD, 2005, Clin Cancer Res, 11, 8570, 10.1158/1078-0432.CCR-05-1047 · DOI
- Sudo T, 2005, Br J Cancer, 92, 1754, 10.1038/sj.bjc.6602531 · DOI
- 10.1038/nature01075 · DOI · Paper page
- Watanabe H, 2008, Cancer Cell Int, 8, 15, 10.1186/1475-2867-8-15 · DOI
- Weikert S, 2005, Int J Mol Med, 16, 349
- Orzan F, 2011, Neuropathol Appl Neurobiol, 37, 381, 10.1111/j.1365-2990.2010.01132.x · DOI
- Zhang R, 2012, Oncol Rep, 28, 2278, 10.3892/or.2012.2033 · DOI
- Smits M, 2010, Oncotarget, 1, 710, 10.18632/oncotarget.205 · DOI
- Crea F, 2010, Mol Cancer, 9, 265, 10.1186/1476-4598-9-265 · DOI · Paper page
- Ott M, 2012, PLoS One, 7, e47663, 10.1371/journal.pone.0047663 · DOI
- Wu Z, 2013, J Neurol Sci, 335, 191, 10.1016/j.jns.2013.09.030 · DOI
- Abdouh M, 2009, J Neurosci, 29, 8884, 10.1523/JNEUROSCI.0968-09.2009 · DOI
- Chan KM, 2013, Genes Dev, 27, 985, 10.1101/gad.217778.113 · DOI · Paper page
- Suva ML, 2009, Cancer Res, 69, 9211, 10.1158/0008-5472.CAN-09-1622 · DOI
- Kim E, 2013, Cancer Cell, 23, 839, 10.1016/j.ccr.2013.04.008 · DOI
- Weng YL, 2013, Neurotherapeutics, 10, 556, 10.1007/s13311-013-0223-4 · DOI
- Rottach A, 2009, J Cell Biochem, 108, 43, 10.1002/jcb.22253 · DOI
- Zhao YE, 2012, Parasitol Res, 110, 2395, 10.1007/s00436-011-2778-5 · DOI
- Brenner C, 2006, Curr Top Microbiol Immunol, 301, 45
- Turek-Plewa J, 2005, Cell Mol Biol Lett, 10, 631
- Roloff TC, 2003, BMC Genomics, 4, 1, 10.1186/1471-2164-4-1 · DOI
- Kimura H, 2003, J Biol Chem, 278, 4806, 10.1074/jbc.M209923200 · DOI
- Cimmino L, 2011, Cell Stem Cell, 9, 193, 10.1016/j.stem.2011.08.007 · DOI
- Frauer C, 2011, PLoS One, 6, e16627, 10.1371/journal.pone.0016627 · DOI
- Iyer L M, 2009, Cell Cycle, 8, 1698, 10.4161/cc.8.11.8580 · DOI
- Wu H, 2011, Nature, 473, 389, 10.1038/nature09934 · DOI · Paper page
- Freudenberg JM, 2012, Nucleic Acids Res, 40, 3364, 10.1093/nar/gkr1253 · DOI
- Rauch T, 2007, Proc Natl Acad Sci USA, 104, 5527, 10.1073/pnas.0701059104 · DOI
- 10.1038/nature04431 · DOI · Paper page
- Kreth S, 2011, PLoS One, 6, e17156, 10.1371/journal.pone.0017156 · DOI
- 10.1053/j.gastro.2009.10.002 · DOI · Paper page
- Pancione M, 2010, PLoS One, 5, e14229, 10.1371/journal.pone.0014229 · DOI
- Cartron PF, 2013, Genes Cancer, 4, 235, 10.1177/1947601913489020 · DOI
- Filipowicz W, 2005, Curr Opin Struct Biol, 15, 331, 10.1016/j.sbi.2005.05.006 · DOI
- 10.1038/nrg1379 · DOI · Paper page
- 10.1093/nar/gkq1027 · DOI · Paper page
- Krol J, 2010, Nat Rev Genet, 11, 597, 10.1038/nrg2843 · DOI · Paper page
- Sontheimer EJ, 2005, Cell, 122, 9, 10.1016/j.cell.2005.06.030 · DOI
- Hong L, 2013, Curr Drug Targets, 14, 1118, 10.2174/13894501113149990183 · DOI
- Pencheva N, 2013, Nat Cell Biol, 15, 546, 10.1038/ncb2769 · DOI
- Yates LA, 2013, Cell, 153, 516, 10.1016/j.cell.2013.04.003 · DOI
- Xiaoping L, 2013, Cell Death Dis, 4, e675, 10.1038/cddis.2013.197 · DOI
- Guo P, 2013, Oncol Rep, 30, 870, 10.3892/or.2013.2526 · DOI
- Rao ZY, 2010, Carcinogenesis, 31, 1576, 10.1093/carcin/bgq150 · DOI
- Ren G, 2012, Cancer Res, 72, 3091, 10.1158/0008-5472.CAN-11-3546 · DOI
- Qiu S, 2013, Biochim Biophys Acta, 1832, 1697, 10.1016/j.bbadis.2013.05.015 · DOI · Paper page
- Lee ST, 2011, J Neurooncol, 102, 19, 10.1007/s11060-010-0286-6 · DOI
- Kong D, 2012, PLoS One, 7, e33729, 10.1371/journal.pone.0033729 · DOI
- Chen Z, 2013, Biomed Res Int, 2013, 695179
- 10.1186/1476-4598-11-51 · DOI
- An L, 2013, PLoS One, 8, e69478, 10.1371/journal.pone.0069478 · DOI
- Lv Z, 2013, Mol Med Rep, 8, 345, 10.3892/mmr.2013.1561 · DOI
- Zheng F, 2012, Gut, 61, 278, 10.1136/gut.2011.239145 · DOI
- Li KK, 2013, Brain Pathol, 23, 426, 10.1111/bpa.12015 · DOI
- Luo C, 2013, J Invest Dermatol, 133, 768, 10.1038/jid.2012.357 · DOI
- Willemsen MH, 2011, J Med Genet, 48, 810, 10.1136/jmedgenet-2011-100294 · DOI · Paper page
- Qian X, 2013, CNS Neurosci Ther, 19, 804, 10.1111/cns.12149 · DOI
- Lu J, 2011, Cancer Res, 71, 225, 10.1158/0008-5472.CAN-10-1850 · DOI
Cited by
Sorted by citations
MiR-128-3p – a gray eminence of the human central nervous system
Kiel, K., Król, S. K., Bronisz, A., & Godlewski, J. (2024) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2024.102141 · Cited by 15
Metadata
- Authors
- Bian, E.-B., Li, J., He, X.-J., Zong, G., Jiang, T., Li, J., & Zhao, B.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2014-07-21
- Volume
- 18
- Issue
- 10
- Pages
- 1197-1206
- ISSN
- 1472-8222
- 1744-7631
- Cited by
- 12
- References
- 2
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review